Queensland’s Deputy Premier, Jarrod Bleijie, recently revealed the name of Australia’s pioneer cGMP biomedical manufacturing facility as ENTRI, situated adjacent to the Translational Research Institute (TRI) in Woolloongabba, Brisbane. This unveiling, graced by the presence of AusBiotech members, underscores ENTRI’s core objective of easing entry barriers for biotech and medtech entities and facilitating the translation of health research from theoretical concepts to practical applications.
Nestled within the Princess Alexandra Hospital campus and the bustling Boggo Road Innovation Precinct in Brisbane, ENTRI’s inauguration marks Queensland’s emergence as the nucleus of biomanufacturing activities across Australia. Supported by the Queensland Government’s heightened focus on biomedical ventures, the facility is a cornerstone of the state’s three new priority industries, bolstered by the substantial $180.6 million Sovereign Industry Development Fund.
As a collaborative initiative between TRI and the Queensland Government, ENTRI represents an investment exceeding AU$100 million. It aims to bridge a fundamental capability gap by providing access to state-of-the-art cleanrooms adhering to global cGMP standards. TRI’s CEO, Professor Maher Gandhi, envisions ENTRI as a catalyst for innovation acceleration, fortifying the health, medtech, and biological domains.
ENRTI’s revolutionary approach garnered praise from stakeholders and industry players, with its promise to forge vital connections with regulatory bodies, government agencies, and research institutions. The facility’s strategic location and seamless integration of manufacturing processes with clinical trials are anticipated to attract international entities keen on leveraging Australia’s R&D Tax Incentive and expedited clinic timelines.
Dr. Ryan Parlett, TRI’s head of commercial operations, highlighted ENTRI’s comprehensive offerings, including cGMP cleanrooms, PC2-compliant wet labs, and office spaces tailored to accommodate biologic, RNA-based products, cell therapies, and drug-device combinations. These facilities are meticulously designed to support Phase 1 to Phase 3 clinical trials, adhering to stringent international and Australian regulatory mandates.
In preparation for ENTRI’s global debut at BIO 2025, TRI has initiated dialogues with key life sciences stakeholders worldwide, setting the stage for a transformative impact on the biomedical landscape. The facility’s flexible infrastructure, combining in-house manufacturing advantages with external site conveniences, promises strategic benefits, operational efficiencies, and sustainable cost savings for occupants and collaborators.
Key Takeaways:
– ENTRI, Queensland’s pioneering cGMP biomedical manufacturing hub, redefines industry standards by facilitating health research translation and fostering biotech and medtech innovations.
– Backed by significant investments from TRI and the Queensland Government, ENTRI fills a critical capability void with its cutting-edge cleanrooms conforming to global cGMP standards.
– The facility’s strategic positioning within Brisbane’s biomedical hub, coupled with its seamless integration of manufacturing processes and clinical trials, is poised to attract international entities seeking to leverage Australia’s incentives and streamlined operational frameworks.
– ENTRI’s comprehensive suite of offerings, including cGMP cleanrooms and wet labs, supports a wide array of products and therapies, positioning it as a pivotal player in driving biomedical advancements and clinical trials.
Tags: quality control, cell therapies, regulatory, biotech
Read more on manmonthly.com.au